SIRT1 at the crossroads of AKT1 and ERβ in malignant pleural mesothelioma cells

Giulia Pinton, Sara Zonca, Arcangela G. Manente, Maria Cavaletto, Ester Borroni, Antonio Daga, Puthen V. Jithesh, Dean Fennell, Stefan Nilsson, Laura Moro

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

In this report, we show that malignant pleural mesothelioma (MPM) patients whose tumors express high levels of AKT1 exhibit a significantly worse prognosis, whereas no significant correlation with AKT3 expression is observed. We provide data that establish a phosphorylation independent role of AKT1 in affecting MPM cell shape and anchorage independent cell growth in vitro and highlight the AKT1 isoform-specific nature of these effects. We describe that AKT1 activity is inhibited by the loss of SIRT1-mediated deacetylation and identify, by mass spectrometry, 11 unique proteins that interact with acetylated AKT1. Our data demonstrate a role of the AKT1/SIRT1/FOXM1 axis in the expression of the tumor suppressor ERβ. We further demonstrate an inhibitory feedback loop by ERβ, activated by the selective agonist KB9520, on this axis both in vitro and in vivo. Our data broaden the current knowledge of ERβ and AKT isoform-specific functions that could be valuable in the design of novel and effective therapeutic strategies for MPM.

Original languageEnglish
Pages (from-to)14366-14379
Number of pages14
JournalOncotarget
Volume7
Issue number12
DOIs
Publication statusPublished - Mar 22 2016

Fingerprint

Protein Isoforms
Cell Shape
Mass Spectrometry
Neoplasms
Phosphorylation
Growth
Malignant Mesothelioma
Proteins
In Vitro Techniques
Therapeutics

Keywords

  • AKT1
  • Estrogen receptor beta
  • Malignant pleural mesothelioma
  • SIRT1

ASJC Scopus subject areas

  • Oncology

Cite this

Pinton, G., Zonca, S., Manente, A. G., Cavaletto, M., Borroni, E., Daga, A., ... Moro, L. (2016). SIRT1 at the crossroads of AKT1 and ERβ in malignant pleural mesothelioma cells. Oncotarget, 7(12), 14366-14379. https://doi.org/10.18632/oncotarget.7321

SIRT1 at the crossroads of AKT1 and ERβ in malignant pleural mesothelioma cells. / Pinton, Giulia; Zonca, Sara; Manente, Arcangela G.; Cavaletto, Maria; Borroni, Ester; Daga, Antonio; Jithesh, Puthen V.; Fennell, Dean; Nilsson, Stefan; Moro, Laura.

In: Oncotarget, Vol. 7, No. 12, 22.03.2016, p. 14366-14379.

Research output: Contribution to journalArticle

Pinton, G, Zonca, S, Manente, AG, Cavaletto, M, Borroni, E, Daga, A, Jithesh, PV, Fennell, D, Nilsson, S & Moro, L 2016, 'SIRT1 at the crossroads of AKT1 and ERβ in malignant pleural mesothelioma cells', Oncotarget, vol. 7, no. 12, pp. 14366-14379. https://doi.org/10.18632/oncotarget.7321
Pinton G, Zonca S, Manente AG, Cavaletto M, Borroni E, Daga A et al. SIRT1 at the crossroads of AKT1 and ERβ in malignant pleural mesothelioma cells. Oncotarget. 2016 Mar 22;7(12):14366-14379. https://doi.org/10.18632/oncotarget.7321
Pinton, Giulia ; Zonca, Sara ; Manente, Arcangela G. ; Cavaletto, Maria ; Borroni, Ester ; Daga, Antonio ; Jithesh, Puthen V. ; Fennell, Dean ; Nilsson, Stefan ; Moro, Laura. / SIRT1 at the crossroads of AKT1 and ERβ in malignant pleural mesothelioma cells. In: Oncotarget. 2016 ; Vol. 7, No. 12. pp. 14366-14379.
@article{9452bc654a2f4e4597f0805402fd97cd,
title = "SIRT1 at the crossroads of AKT1 and ERβ in malignant pleural mesothelioma cells",
abstract = "In this report, we show that malignant pleural mesothelioma (MPM) patients whose tumors express high levels of AKT1 exhibit a significantly worse prognosis, whereas no significant correlation with AKT3 expression is observed. We provide data that establish a phosphorylation independent role of AKT1 in affecting MPM cell shape and anchorage independent cell growth in vitro and highlight the AKT1 isoform-specific nature of these effects. We describe that AKT1 activity is inhibited by the loss of SIRT1-mediated deacetylation and identify, by mass spectrometry, 11 unique proteins that interact with acetylated AKT1. Our data demonstrate a role of the AKT1/SIRT1/FOXM1 axis in the expression of the tumor suppressor ERβ. We further demonstrate an inhibitory feedback loop by ERβ, activated by the selective agonist KB9520, on this axis both in vitro and in vivo. Our data broaden the current knowledge of ERβ and AKT isoform-specific functions that could be valuable in the design of novel and effective therapeutic strategies for MPM.",
keywords = "AKT1, Estrogen receptor beta, Malignant pleural mesothelioma, SIRT1",
author = "Giulia Pinton and Sara Zonca and Manente, {Arcangela G.} and Maria Cavaletto and Ester Borroni and Antonio Daga and Jithesh, {Puthen V.} and Dean Fennell and Stefan Nilsson and Laura Moro",
year = "2016",
month = "3",
day = "22",
doi = "10.18632/oncotarget.7321",
language = "English",
volume = "7",
pages = "14366--14379",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "12",

}

TY - JOUR

T1 - SIRT1 at the crossroads of AKT1 and ERβ in malignant pleural mesothelioma cells

AU - Pinton, Giulia

AU - Zonca, Sara

AU - Manente, Arcangela G.

AU - Cavaletto, Maria

AU - Borroni, Ester

AU - Daga, Antonio

AU - Jithesh, Puthen V.

AU - Fennell, Dean

AU - Nilsson, Stefan

AU - Moro, Laura

PY - 2016/3/22

Y1 - 2016/3/22

N2 - In this report, we show that malignant pleural mesothelioma (MPM) patients whose tumors express high levels of AKT1 exhibit a significantly worse prognosis, whereas no significant correlation with AKT3 expression is observed. We provide data that establish a phosphorylation independent role of AKT1 in affecting MPM cell shape and anchorage independent cell growth in vitro and highlight the AKT1 isoform-specific nature of these effects. We describe that AKT1 activity is inhibited by the loss of SIRT1-mediated deacetylation and identify, by mass spectrometry, 11 unique proteins that interact with acetylated AKT1. Our data demonstrate a role of the AKT1/SIRT1/FOXM1 axis in the expression of the tumor suppressor ERβ. We further demonstrate an inhibitory feedback loop by ERβ, activated by the selective agonist KB9520, on this axis both in vitro and in vivo. Our data broaden the current knowledge of ERβ and AKT isoform-specific functions that could be valuable in the design of novel and effective therapeutic strategies for MPM.

AB - In this report, we show that malignant pleural mesothelioma (MPM) patients whose tumors express high levels of AKT1 exhibit a significantly worse prognosis, whereas no significant correlation with AKT3 expression is observed. We provide data that establish a phosphorylation independent role of AKT1 in affecting MPM cell shape and anchorage independent cell growth in vitro and highlight the AKT1 isoform-specific nature of these effects. We describe that AKT1 activity is inhibited by the loss of SIRT1-mediated deacetylation and identify, by mass spectrometry, 11 unique proteins that interact with acetylated AKT1. Our data demonstrate a role of the AKT1/SIRT1/FOXM1 axis in the expression of the tumor suppressor ERβ. We further demonstrate an inhibitory feedback loop by ERβ, activated by the selective agonist KB9520, on this axis both in vitro and in vivo. Our data broaden the current knowledge of ERβ and AKT isoform-specific functions that could be valuable in the design of novel and effective therapeutic strategies for MPM.

KW - AKT1

KW - Estrogen receptor beta

KW - Malignant pleural mesothelioma

KW - SIRT1

UR - http://www.scopus.com/inward/record.url?scp=84971671278&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84971671278&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.7321

DO - 10.18632/oncotarget.7321

M3 - Article

AN - SCOPUS:84971671278

VL - 7

SP - 14366

EP - 14379

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 12

ER -